Key Points
- Insider sale: EVP Michael Feld sold 76 BDX shares for approximately $13,961 at an average price of $183.70 under a pre-arranged Rule 10b5-1 plan. He continues to own 19,644 shares.
- Financial performance: BD reported quarterly EPS of $3.23, exceeding estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion. The company guided to fiscal 2026 EPS of $12.62–$12.72.
- Market outlook: BDX trades near $182, and analysts have a consensus “Hold” rating with an average price target of $187.67. The company also declared a quarterly dividend of $1.05 per share, yielding about 2.3% annually.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 76 shares of the firm's stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $183.70, for a total transaction of $13,961.20. Following the transaction, the executive vice president directly owned 19,644 shares in the company, valued at approximately $3,608,602.80. This represents a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Feld also recently made the following trade(s):
- On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $188.49, for a total value of $31,100.85.
- On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $157.13, for a total value of $11,784.75.
Becton, Dickinson and Company Trading Down 1.0%
BDX opened at $182.03 on Wednesday. The company has a 50-day simple moving average of $179.26 and a 200 day simple moving average of $161.33. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $193.07. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $50.16 billion, a price-to-earnings ratio of 54.83, a P/E/G ratio of 12.96 and a beta of 0.21.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the firm posted $3.68 earnings per share. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio is 126.51%.
Institutional Investors Weigh In On Becton, Dickinson and Company
Hedge funds and other institutional investors have recently modified their holdings of the stock. TD Waterhouse Canada Inc. grew its holdings in shares of Becton, Dickinson and Company by 17.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier's stock valued at $14,715,000 after purchasing an additional 14,077 shares during the last quarter. Northside Capital Management LLC lifted its holdings in Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier's stock worth $9,280,000 after buying an additional 9,494 shares during the period. NewEdge Advisors LLC boosted its holdings in Becton, Dickinson and Company by 35.0% in the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier's stock valued at $6,923,000 after acquiring an additional 11,414 shares in the last quarter. Wealthfront Advisers LLC purchased a new position in shares of Becton, Dickinson and Company during the second quarter valued at about $2,567,000. Finally, Beverly Hills Private Wealth LLC purchased a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $3,353,000. 86.97% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages have recently commented on BDX. Citigroup reiterated a "buy" rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Friday, August 7th. Jefferies Financial Group restated a "buy" rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Weiss Ratings raised shares of Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday. Eight research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $187.67.
Check Out Our Latest Stock Analysis on BDX
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.
BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
